Specialty Pharmacy

This indication has received accelerated approval based on tumor response rate and durability of response, though the results of confirmatory trials may change the approval status.

The study is most comprehensive analysis to date of changes in hospital mortality throughout the pandemic, reviewing data on more than 20,000 patients admitted to hospitals for COVID-19 over 9 months, according to the Institute for Health Metrics and Evaluation at the University of Washington.

IQVIA researchers saw a sharp uptick in medication usage shortly before the COVID-19 pandemic began, followed by a steep fall in the first few months of the pandemic.

The study also found that patients with comorbidities such as heart disease and diabetes were more likely to experience a high symptom burden.

An interim analysis from the phase 3 ALPINE trial comparing zanubrutinib against ibrutinib demonstrated positive results in the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Health care practitioners and manufacturers must change practice patterns and management strategies.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

Individuals with an average risk of colorectal cancer said they would prefer a stool-based screening test for colorectal cancer over colonoscopy.

The relatively new combination of PD-1/PD-L1 inhibitors with VEGF inhibitors represents a promising option for patients with various malignancies.

Although therapeutics and vaccines for COVID-19 have dominated the news in the last year, development of other drugs has continued.

A metanalysis published in SN Comprehensive Clinical Medicine found that administering the therapies early in a patient’s treatment could be associated with better outcomes.

Directions in Oncology Pharmacy® is getting to know oncology pharmacy professionals through a series of interviews. In this issue, we talk to David DeRemer, PharmD, BCOP, FCCP, FHOPA, president of the Hematology/Oncology Pharmacy Association (HOPA) Board of Directors, whose term ends this month.

The Star Rating for Biosimilars Act, HR 2855, aims to create a biosimilars access measure in the Centers for Medicare and Medicaid Services’ Star Ratings Program.

Cynthia Lynch, MD, breast cancer program clinical advisor with Cancer Treatment Centers of America, said oncology pharmacists are vital team members who can help ensure optimal treatment and safety for patients with breast cancer.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

B cell activating factor appears to promote antibodies against, and inhibitors of, the missing blood clotting factor that is given to patients with hemophilia A to control their bleeding.

The study further explored the various aspects of financial hardships, including material, psychological, and behavioral measures.

Community pharmacists should consider leaning on their specialty pharmacist peers, where available, as we continue to navigate the new, more virtual normal and attempt to expand these types of services in the future.

Health systems individually have struggled to demonstrate improvements to total cost of care because, without data about patients they do not serve, they cannot define a comparison group.

One mutated version of KRAS that commonly arises in cancer cells is called KRAS(G12C) and it produces a mutated KRAS protein that allows the cells to grow and spread in the body.

The study shows that brentuximab vedotin allowed for reduced radiation exposures and resulted in fewer adverse effects for patients, according to its authors.

Pharmacy Times spoke with spinal muscular atrophy (SMA) patient Nick Sinagra about his treatment journey and his experiences with 2 different SMA treatments.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

A new study led by researchers at NYU Rory Meyers College of Nursing found that breast cancer survivors with a higher risk of cancer recurrence based on genomic testing may experience greater fear of their cancer returning.

Nivolumab is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival compared to chemotherapy alone in this patient population.

Hematology/Oncology Pharmacy Association plans to develop tools and resources to support those conducting research in the oncology pharmacy field, with the goal of promoting pharmacist-led research and improving the ability to analyze difficult scientific questions.

Ependymoma is a rare type of tumor that develops in the brain or spinal cord and can occur at any age, but occurs most frequently in young children.

Promising investigational oncology drugs include oral taxanes, small molecule drugs, and immunotherapies.

Common factors that contributed to reported increased dissatisfaction at work include role conflict, quantity of work, workflow disruptions, organizational culture, and leadership support.

Even while therapeutically anticoagulated, patients with cancer have risk factors for recurring venous thromboembolism and bleeding, according to a session at the Hematology/Oncology Pharmacy Association 2021 Virtual Annual Conference.